摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

环丙基羰基丙二酸二乙酯 | 7394-16-3

中文名称
环丙基羰基丙二酸二乙酯
中文别名
——
英文名称
diethyl cyclopropylcarbonylmalonate
英文别名
1,3-Diethyl 2-cyclopropanecarbonylpropanedioate;diethyl 2-(cyclopropanecarbonyl)propanedioate
环丙基羰基丙二酸二乙酯化学式
CAS
7394-16-3
化学式
C11H16O5
mdl
——
分子量
228.245
InChiKey
XBJPBRKJNPXNFS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    124 °C
  • 密度:
    1.195±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    16
  • 可旋转键数:
    8
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.73
  • 拓扑面积:
    69.7
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    环丙基羰基丙二酸二乙酯三正丁胺三乙胺 、 potassium hydroxide 、 三氯氧磷 作用下, 以 乙醇甲苯 为溶剂, 反应 28.0h, 生成 乙基3-环丙基-2-丙炔酸酯
    参考文献:
    名称:
    UTILIZATION OF b-CHLORO ALKYLIDENE/ARYLIDENE MALONATES IN ORGANIC SYNTHESIS: ETHYL CYCLOPROPYLPROPIOLATE
    摘要:
    DOI:
    10.15227/orgsyn.066.0173
  • 作为产物:
    参考文献:
    名称:
    Discovery of the bifunctional modulator of angiotensin II type 1 receptor (AT1R) and PPARγ derived from the AT1R antagonist, Fimasartan
    摘要:
    Inspired by the well-known PPAR gamma partial agonism of angiotensin II type 1 receptor (AT1R) antagonists exemplified by an antihypertensive drug, Telmisartan, efforts to identify compounds with the dual activities have been pursued in order to control the two major metabolic disorders, hypertension and hyperglycemia simultaneously. Lead compound 18 derived from the AT1R antagonist, Fimasartan, has successfully presented the possibility to control the medical conditions by a single molecule.
    DOI:
    10.1016/j.bmcl.2018.08.036
点击查看最新优质反应信息

文献信息

  • Potent biological investigation into a new class of sulfone derivatives endowed with quinolinyl–cyclopropane analogue
    作者:Janki J. Patel、Mayur I. Morja、Prakashsingh M. Chauhan、Kishor H. Chikhalia
    DOI:10.1007/s13738-021-02402-w
    日期:2022.5
    Novel series of quinoline derivatives incorporating cyclopropyl ring and sulfone linkage as substituents have been synthesized, and oxidation of ethyl-2-cyclopropyl-4-(substituted phenylthio)quinoline-3-carboxylate was carried out to set ethyl-2-cyclopropyl-4-(substituted phenyl sulfonyl)quinoline-3-carboxylate. An ecofriendly synthesis of sulfone derivatives was carried out by the reaction of glacial
    合成了一系列以环丙基环和砜键为取代基的新型喹啉衍生物,并通过氧化乙基-2-环丙基-4-(取代苯硫基)喹啉-3-羧酸酯形成乙基-2-环丙基-4- (取代的苯基磺酰基)喹啉-3-羧酸酯。通过冰醋酸和30%的过氧化氢在室温下反应,进行了环境友好的砜衍生物合成。对合成的含有砜连接衍生物的喹啉进行了预期的抗菌活性评估,并通过它们的熔点、质谱、IR、1 H NMR 和13C 核磁共振谱。为了证明结构生物活性,我们在这里进行了 SAR 和 HOMO-LUMO 研究。从这些研究中,我们发现了一些最好的结果,因为它们的能隙非常低,这使得它们的活性更高,即化合物11a、11b、11h、11k和11m。 图形概要
  • Enol elimination reactions. Part III. The scope and limitations of eliminations involving enol sulphonates
    作者:E. J. D. Brown、John Harley-Mason
    DOI:10.1039/j39660001390
    日期:——
    Elimination reactions of enol sulphonates have been further studied. The enol sulphonates of p-anisolyl-, 2-furoyl-, and 2-thenoyl-malonic esters readily gave the corresponding propiolic acids on treatment with base, whereas the enol sulphonates of o-, m-, and p-nitrobenzoylmalonic esters gave negligible yields. The enol sulphonates of cyclopropylcarbonylmalonate gave cyclopropylpropiolic acid, while
    烯醇磺酸盐的消除反应已被进一步研究。的烯醇磺酸盐p -anisolyl-,2-糠酰基,2-噻吩甲酰基,丙二酸酯容易介绍了用碱处理相应的丙炔酸,而烯醇磺酸盐ø - ,米- ,和p -nitrobenzoylmalonic酯,得到可忽略的产量。环丙基羰基丙二酸酯的烯醇磺酸盐得到环丙基丙酸,而三氯乙酰基丙二酸酯和富马酰基丙二酸酯的烯醇磺酸盐不产生炔属产物。三苯甲酰基甲烷的烯醇磺酸盐得到苯甲酰基苯基-乙炔。
  • [EN] PYRAZOLO '3,4-B! PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS<br/>[FR] COMPOSES DE PYRAZOLO 3,4-B! PYRIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PHOSPHODIESTERASE DE TYPE 4 (PDE4)
    申请人:GLAXO GROUP LTD
    公开号:WO2005090348A1
    公开(公告)日:2005-09-29
    The invention provides a compound of formula (I) or a salt thereof: formula (I) wherein W is Ar, -CR4R5Ar or a group (y) or (y1), wherein Ar is (x) or (z): formulae (x), (z), (y), (y1) R1 is C1-4alkyl, C1-3fluoroalkyl or CH2CH2OH. R2 is C2-6alkyl, C3-6cycloalkyl or -(CH2)n4-C3-6cycloalkyl; and R3 is optionally substituted C3-8cycloalkyl, optionally substituted mono unsaturated C5-7cycloalkenyl, an optionally substituted heterocyclic group (aa), (bb) or (cc) (in which Y is O, S, SO2, or NR10), or a bicyclic group (ee): formulae (aa), (bb), (cc), (ee). The invention also relates to the use of the compounds in therapy as inhibitors of phosphodiesterase type IV (PDE4), and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis or allergic rhinitis.
    该发明提供了式(I)的化合物或其盐:式(I)其中W是Ar,-CR4R5Ar或(y)或(y1)的基团,其中Ar是(x)或(z):式(x),(z),(y),(y1);R1是C1-4烷基,C1-3氟代烷基或CH2CH2OH;R2是C2-6烷基,C3-6环烷基或-(CH2)n4-C3-6环烷基;R3是可选取代的C3-8环烷基,可选取代的单不饱和C5-7环烯基,可选取代的杂环基(aa),(bb)或(cc)(其中Y是O,S,SO2或NR10),或双环基(ee):式(aa),(bb),(cc),(ee)。该发明还涉及将该化合物用于治疗作为磷酸二酯酶IV(PDE4)的抑制剂,并/或用于治疗和/或预防炎症和/或过敏性疾病,例如慢性阻塞性肺疾病(COPD),哮喘,类风湿性关节炎或过敏性鼻炎。
  • Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors
    申请人:Allen George David
    公开号:US20080021058A1
    公开(公告)日:2008-01-24
    The invention provides a compound of formula (I) or a salt thereof: wherein W is Ar, —CR 4 R 5 Ar or a group (y) or (y1), wherein Ar is (x) or (z): R 1 is C 1-4 alkyl, C 1-3 fluoroalkyl or —CH 2 CH 2 OH. R 2 is C 2-6 alkyl, C 3-6 cycloalkyl or —(CH 2 ) n 4-C 3-6 cycloalkyl; and R 3 is optionally substituted C 3-8 cycloalkyl, optionally substituted mono-unsaturated-C 5-7 cycloalkenyl, an optionally substituted heterocyclic group (aa), (bb) or (cc) (in which Y is O, S, SO 2 , or NR 10 ), or a bicyclic group (ee): These compounds are PDE4 inhibitors.
    本发明提供了式(I)的化合物或其盐:其中,W为Ar,—CR4R5Ar或(y)或(y1)基团,其中Ar为(x)或(z):R1为C1-4烷基,C1-3氟烷基或—CH2CH2OH;R2为C2-6烷基,C3-6环烷基或—(CH2)n4-C3-6环烷基;R3为可选取代的C3-8环烷基,可选取代的单不饱和C5-7环戊烯基,可选取代的杂环基(aa)、(bb)或(cc)(其中Y为O、S、SO2或NR10),或双环基(ee)。这些化合物是PDE4抑制剂。
  • Hormi, Osmo E. O., Synthetic Communications, 1986, vol. 16, # 9, p. 997 - 1002
    作者:Hormi, Osmo E. O.
    DOI:——
    日期:——
查看更多